CONTE LISA A

SEC source: 0001193125-26-018040 · ownership.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,592

Underlying: Common Stock · 28,592 shares

Expires 2035-12-11

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

F4 · derivative.exercise_date: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

SEC source: 0001193125-26-018040 · ownership.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,258

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

SEC source: 0000950170-25-090433 · ownership.xml · derivative · entry 3

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 18,262 shares

Expires 2026-12-24

F2 · price: As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.

F2 · derivative.exercise_date: As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.

SEC source: 0000950170-25-090433 · ownership.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,462

Underlying: Common Stock · 9,462 shares

Expires not disclosed

F1 · price: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

F1 · derivative.exercise_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

F1 · derivative.expiration_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

SEC source: 0000950170-25-090433 · ownership.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires not disclosed

F1 · price: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

F1 · derivative.exercise_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

F1 · derivative.expiration_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

SEC source: 0000950170-25-075332 · ownership.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "May 2024 Reverse Stock Split). Upon effectiveness of the May 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 18, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "March 2025 Reverse Stock Split").

F3 · derivative.exercise_price: (Continued from footnote 2) Upon effectiveness of the March 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

F4 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split, May 2024 Reverse Stock Split and March 2025 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

F4 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split, May 2024 Reverse Stock Split and March 2025 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

SEC source: 0000950170-25-075332 · ownership.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "May 2024 Reverse Stock Split). Upon effectiveness of the May 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 18, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "March 2025 Reverse Stock Split").

F3 · balance_after: (Continued from footnote 2) Upon effectiveness of the March 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0000950170-25-049806 · ownership.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2030-03-31

F2 · price: As an inducement to enter into the Purchase Agreement, the reporting person received a warrant (the "Warrant") to purchase up to 9,000 shares of Common Stock with an exercise price of $5.43 per share. The Warrant is exercisable immediately upon issuance and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.

SEC source: 0000950170-25-049806 · ownership.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires not disclosed

F1 · price: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,000 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

F1 · derivative.exercise_date: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,000 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

F1 · derivative.expiration_date: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,000 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

SEC source: 0000950170-24-114187 · ownership.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,020

Underlying: Common Stock · 132,020 shares

Expires 2034-10-08

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024.

F5 · derivative.exercise_date: The options will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.

SEC source: 0000950170-24-114187 · ownership.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,624

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024.

F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest in three equal annual installments beginning on October 8, 2025. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice.

F4 · balance_after: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the " Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0001104659-24-063892 · tm2414996-3_4seq1.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,694

Underlying: Common Stock · 2,695 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock.

F3 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

F3 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

SEC source: 0001104659-24-063892 · tm2414996-3_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0001104659-24-048338 · tm2411853-2_4seq1.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.

F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.

F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.

SEC source: 0001104659-24-048338 · tm2411853-2_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001104659-23-091447 · tm2320633-2_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 387,605

SEC source: 0001104659-23-062738 · tm2316214-6_4seq1.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,389

Underlying: Common Stock · 2,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock.

F3 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

F3 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

SEC source: 0001104659-23-062738 · tm2316214-6_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0001104659-23-047871 · tm2311973-6_4seq1.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600

Underlying: Common Stock · 600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.

F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.

F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.

SEC source: 0001104659-23-047871 · tm2311973-6_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,306

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0001104659-22-130629 · tm2233639-3_4seq1.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 142,500 shares

Expires 2031-04-05

F2 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.

F1 · balance_after: The option was cancelled by mutual agreement of the reporting person and Jaguar Health, Inc. The reporting person received $300 as consideration for the cancellation.

SEC source: 0001104659-22-043237 · tm2211739-4_4seq1.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_price: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.

F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.

F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.

SEC source: 0001104659-22-043237 · tm2211739-4_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,003

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · balance_after: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0001104659-22-040391 · tm2210715-10_4seq1.xml · derivative · entry 3

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F2 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F4 · date: The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.

F6 · derivative.exercise_date: The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe.

F6 · derivative.expiration_date: The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe.

SEC source: 0001104659-22-040391 · tm2210715-10_4seq1.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 606,280

Underlying: Common Stock · 606,280 shares

Expires not disclosed

F2 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F4 · date: The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.

F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

SEC source: 0001104659-22-040391 · tm2210715-10_4seq1.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,003

F1 · balance_after: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.

SEC source: 0001104659-21-047557 · a4.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,000

Underlying: Common Stock · 405,000 shares

Expires not disclosed

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021.

F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice.

F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice.

SEC source: 0001104659-21-047557 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,000

Underlying: Common Stock · 810,000 shares

Expires 2031-04-05

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021.

F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.

SEC source: 0001104659-20-037925 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,293

Underlying: Common Stock · 238,293 shares

Expires 2030-03-20

F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan.

F2 · date: The option grant was approved by the issuer's board of directors on March 20, 2020.

F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.

SEC source: 0001104659-19-041839 · a4.xml · derivative · entry 2

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,042,052

Underlying: Common Stock · 1,042,052 shares

Expires 2022-07-24

F3 · security: Granted pursuant to the issuer's 2014 Equity Incentive Plan.

F4 · date: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering described in note 1 above. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on 7/24/19, such that the effective date of the option grant was 7/24/19.

F5 · derivative.exercise_date: Vests in equal monthly installments beginning on July 24, 2019, with five months of options, or 144,729 options, vested as of the grant date based on the reporting person's number of years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date.

SEC source: 0001104659-19-041839 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2024-06-07

F2 · price: The reporting person purchased a 12% promissory notes and received a bridge warrant in connection therewith, which was exercisable for a number of shares of voting common stock equal to 75% of the principal amount of the promissory note divided by the exercise price of $2.00.

F1 · derivative.expiration_date: The bridge warrant was issued pursuant to a purchase agreement dated June 7, 2019, but the exercise price was not determinable until the closing of the issuer's underwritten public offering on July 23, 2019. The bridge warrant is exercisable upon the consummation of such underwritten public offering for a period of five years from the date of issuance, unless earlier terminated upon occurrence of certain events as set forth in the terms of the warrant. The exercise price for the bridge warrant is $2.00, calculated as the per share price at which the issuer issued securities in the underwritten public offering.

SEC source: 0001104659-18-045787 · a4.xml · nonDerivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

SEC source: 0001104659-18-038707 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 447,935

Underlying: Common Stock · 447,935 shares

Expires 2028-04-12

F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan

F2 · security: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018.

F3 · date: The option grant was approved by the Issuer's board of directors on April 12, 2018, subject to the stockholders approving and effecting a reverse stock split. The Issuer's shareholders approved the reverse stock split on May 18, 2018 and effected such stock split on June 1, 2018.

F4 · derivative.exercise_date: Vests in equal monthly installments, beginning on May 1, 2018, such that it is vested in full on the 3-year anniversary of the grant date.

SEC source: 0001104659-18-017522 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,247,242

Underlying: Common Stock · 3,247,242 shares

Expires 2027-08-02

F1 · security: Granted pursuant to the Issuer's 2014 Stock Incentive Plan.

F2 · date: The option grant was approved by the Issuer's board of directors on August 2, 2017, subject to shareholder approval of the amendment to the 2014 Stock Incentive Plan. The Issuer's shareholders approved the amendment on March 12, 2018.

F3 · derivative.exercise_date: Vests in equal monthly installments, beginning August 2, 2017, such that it is vested in full on the 3-year anniversary of the grant date.

SEC source: 0001104659-17-075717 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,807

Underlying: Common Stock · 285,807 shares

Expires 2027-12-21

F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan

F2 · derivative.exercise_date: Vests in full on March 31, 2018 if reporting person is an employee as of such date.

SEC source: 0001104659-16-163171 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,998

Underlying: Common Stock · 16,998 shares

Expires 2026-12-19

F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan

F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on January 19, 2017, such that it is vested in full on the 3-year anniversary of the grant date.

SEC source: 0001104659-16-146279 · a4.xml · derivative · entry 1

CONTE LISA A · CIK 0001008377 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,000

Underlying: Common Stock · 318,000 shares

Expires 2026-09-22

F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan

F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on October 22, 2016, such that it is vested in full on the 3-year anniversary of the grant date.